Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Interleukin-15 and irisin serum concentrations are not related to cardiometabolic risk factors in patients with type 2 diabetes from Korea and Germany.

Choi KM, Hwang SY, Han K, Chung HS, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Ebert T, Fasshauer M, Blüher M.

Acta Diabetol. 2019 Sep 10. doi: 10.1007/s00592-019-01417-3. [Epub ahead of print] No abstract available.

PMID:
31506722
2.

Associations of Circulating Irisin Concentrations With Cardiometabolic Risk Factors Among Children Vary by Physical Activity or Sedentary Time Levels.

Cai L, Tan M, Tan W, Zeng X, Wan N, Wong SH, O'Reilly J, Sun F, Yang J, Chen Y.

Front Endocrinol (Lausanne). 2019 Aug 14;10:549. doi: 10.3389/fendo.2019.00549. eCollection 2019.

3.

Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy.

Hu W, Wang R, Li J, Zhang J, Wang W.

Ann Clin Biochem. 2016 Jan;53(Pt 1):67-74. doi: 10.1177/0004563215582072. Epub 2015 Mar 26.

PMID:
25814621
4.

Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study.

Herder C, Kannenberg JM, Carstensen-Kirberg M, Huth C, Meisinger C, Koenig W, Peters A, Rathmann W, Roden M, Thorand B.

Cardiovasc Diabetol. 2017 Jan 31;16(1):17. doi: 10.1186/s12933-017-0498-6.

5.

Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

García-Fontana B, Reyes-García R, Morales-Santana S, Ávila-Rubio V, Muñoz-Garach A, Rozas-Moreno P, Muñoz-Torres M.

Endocrine. 2016 Apr;52(1):54-62. doi: 10.1007/s12020-015-0758-8. Epub 2015 Oct 5.

PMID:
26438394
6.

Irisin modulates the association of interleukin-17A with the presence of non-proliferative diabetic retinopathy in patients with type 2 diabetes.

Wang C, Wang L, Liu J, Song J, Sun Y, Lin P, Liang K, Liu F, He T, Sun Z, Hou X, Chen L.

Endocrine. 2016 Aug;53(2):459-64. doi: 10.1007/s12020-016-0905-x. Epub 2016 Mar 3.

PMID:
26940815
7.

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors.

Stratigou T, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Christodoulatos GS, Karampela I, Papavassiliou AG.

Endocrine. 2018 Jul;61(1):83-93. doi: 10.1007/s12020-018-1550-3. Epub 2018 Feb 17.

PMID:
29455364
8.

Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study.

Buscemi S, Corleo D, Vasto S, Buscemi C, Massenti MF, Nuzzo D, Lucisano G, Barile AM, Rosafio G, Maniaci V, Giordano C.

Int J Obes (Lond). 2018 Mar;42(3):398-404. doi: 10.1038/ijo.2017.255. Epub 2017 Oct 13.

PMID:
29027533
9.

Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations.

Ebert T, Kralisch S, Wurst U, Scholz M, Stumvoll M, Kovacs P, Fasshauer M, Tönjes A.

Int J Obes (Lond). 2016 Feb;40(2):260-5. doi: 10.1038/ijo.2015.157. Epub 2015 Aug 19.

PMID:
26285604
10.

Irisin in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS.

Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18.

PMID:
24140091
11.

Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study.

Carstensen-Kirberg M, Kannenberg JM, Huth C, Meisinger C, Koenig W, Heier M, Peters A, Rathmann W, Roden M, Herder C, Thorand B.

Cardiovasc Diabetol. 2017 Aug 29;16(1):109. doi: 10.1186/s12933-017-0591-x.

12.

Serum irisin levels in new-onset type 2 diabetes.

Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG.

Diabetes Res Clin Pract. 2013 Apr;100(1):96-101. doi: 10.1016/j.diabres.2013.01.007. Epub 2013 Jan 29.

PMID:
23369227
13.

The ratio of skeletal muscle mass to visceral fat area is a main determinant linking circulating irisin to metabolic phenotype.

Hwang YC, Jeon WS, Park CY, Youn BS.

Cardiovasc Diabetol. 2016 Jan 20;15:9. doi: 10.1186/s12933-015-0319-8.

14.

Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study.

Sahin-Efe A, Upadhyay J, Ko BJ, Dincer F, Park KH, Migdal A, Vokonas P, Mantzoros C.

Metabolism. 2018 Feb;79:24-32. doi: 10.1016/j.metabol.2017.10.011. Epub 2017 Nov 3.

PMID:
29108900
15.

Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes.

Wang HH, Zhang XW, Chen WK, Huang QX, Chen QQ.

J Diabetes Complications. 2015 Apr;29(3):384-9. doi: 10.1016/j.jdiacomp.2015.01.001. Epub 2015 Jan 9.

PMID:
25623634
16.

High Serum Irisin Level as an Independent Predictor of Diabetes Mellitus: A Longitudinal Population-Based Study.

Huh JH, Ahn SV, Choi JH, Koh SB, Chung CH.

Medicine (Baltimore). 2016 Jun;95(23):e3742. doi: 10.1097/MD.0000000000003742.

17.

Circulating irisin in relation to insulin resistance and the metabolic syndrome.

Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS.

J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907. doi: 10.1210/jc.2013-2373. Epub 2013 Sep 20. Erratum in: J Clin Endocrinol Metab. 2014 May;99(5):1910.

18.

The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Ansari S, Djalali M, Mohammadzadeh Honarvar N, Mazaherioun M, Zarei M, Agh F, Gholampour Z, Javanbakht MH.

Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614. doi: 10.5812/ijem.40614. eCollection 2017 Jan.

19.

Association of serum concentrations of irisin and the adipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients.

Kaneda H, Nakajima T, Haruyama A, Shibasaki I, Hasegawa T, Sawaguchi T, Kuwata T, Obi S, Arikawa T, Sakuma M, Amano H, Toyoda S, Fukuda H, Inoue T.

PLoS One. 2018 Aug 2;13(8):e0201499. doi: 10.1371/journal.pone.0201499. eCollection 2018.

20.

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.

Feng X, Gao X, Jia Y, Zhang H, Pan Q, Yao Z, Yang N, Liu J, Xu Y, Wang G, Yang X.

PPAR Res. 2015;2015:924131. doi: 10.1155/2015/924131. Epub 2015 Nov 26.

Supplemental Content

Support Center